Impactiviti Daily 120109

Welcome back from Thanksgiving holiday! Can’t believe it’s already December… This will be the only Impactiviti Daily this week, as I am heading down to South Carolina for the graduation of my #2 son (David) from Marine boot camp. TODAY’S NEWS Layoffs. Sanofi reps are apparently getting the news this week. Ugh. Will Celgene‘s Revlimid [...]

Read Full Post »

Impactiviti Daily 112409

I wish all my readers and pharma-industry colleagues a wonderful Thanksgiving holiday! TODAY’S NEWS Cephalon, Ception, and CINQUIL: the stats don’t reach significance, but at least all the names are similar – “We are pleased to see a positive biological effect of CINQUIL,” said Steve Tullman, Chief Executive Officer at Ception Therapeutics. “Conducting clinical studies [...]

Read Full Post »

Pfizer and Social Media – an Update

I enjoy seeing ANY kind of progress in pharma’s use of social media – most of us who are involved realize that we’re still going to be in the shallow end of the pool for a while (with all the regulatory uncertainty) – but when any company tries to responsibly move the needle, they deserve [...]

Read Full Post »

Impactiviti Daily 112309

It’s Thanksgiving week! We’ll plan on publishing the Daily on Monday/Tuesday, then take the rest of the week off from news reporting. Unless somebody buys somebody else. That, we’ll report! TODAY’S NEWS Sanofi chief wants to do things differently. Liked this juicy quote:  Mr Viehbacher added: “The best scientists are often lousy leaders [and] managers. [...]

Read Full Post »

Impactiviti Daily 112009

TODAY’S NEWS So, have we been pursuing the wrong course for GERD all this time? Is it actually caused by immune system cells, not stomach acid? Maybe cheap/old/tried-and-true really is better. Diuretics for HPB, for instance. Or just plain generic simvastatin for cholesterol. Pfizer gets good news on Revatio (which is the same as Viagra, [...]

Read Full Post »

Impactiviti Daily 111709

Whew! The back-to-back conference marathon is now over, and we can get back to our regular pharma news reporting. Here’s what’s up today… TODAY’S NEWS Everyone’s talking about the Zetia/Niaspan study – its results, its significance, its limitations. Bottom line – I can’t see how this can be good for Merck. More here. And Jim [...]

Read Full Post »

The Pitfall of Doing Nothing

[I'm talking pharma here. But just swap in your industry and the argument will likely apply!] Here in the highly regulated prairies of pharma-land, there is a fair amount of fear and trembling about drug companies getting involved with social networking. Many of the discussions start and end with the perceived potential pitfalls (lots of [...]

Read Full Post »

Impactiviti Daily 110209

TODAY’S NEWS Takeda buys into Amylin‘s weight-loss drug portfolio – Takeda will pay $75 million upfront for medicines including Amylin’s pramlintide/metreleptin and davalintide, in the second phase of testing needed for U.S. regulatory approval, Osaka- based Takeda and San Diego-based Amylin said in a statement…more Plus, quickie update on three other anti-obesity drugs being developed [...]

Read Full Post »